SG11201804263PA - Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor - Google Patents

Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Info

Publication number
SG11201804263PA
SG11201804263PA SG11201804263PA SG11201804263PA SG11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA SG 11201804263P A SG11201804263P A SG 11201804263PA
Authority
SG
Singapore
Prior art keywords
bothell
drive
international
washington
fucose
Prior art date
Application number
SG11201804263PA
Inventor
Shyra Gardai
Che-Leung Law
Peter Senter
Nicole Okeley
Jessica Field
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG11201804263PA publication Critical patent/SG11201804263PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau ristspi id (43) International Publication Date .... .....r ,„„0 8 June 2017 (08.06.2017) W I P0 1 PCT ID Hit (10) 11111111 WO Ill International 1111111111 IIIII II 2017/096274 III IIIIIIIIIIIIIII Publication IIIIIIIIIIIIII Al Number RIO IIII IIIIIIII (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/7024 (2006.01) A61K 39/395 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/7042 (2006.01) C07K 16/28 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/70 (2006.01) C07K 16/32 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 31/02 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, PCT/US2016/064783 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 2 December 2016 (02.12.2016) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/263,228 4 December 2015 (04.12.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/308,583 15 March 2016 (15.03.2016) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/321,857 13 April 2016 (13.04.2016) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: SEATTLE GENETICS, INC. [US/US]; LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 21823 30th Drive SE, Bothell, Washington 98021 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors: GARDAI, Shyra; 21823 30th Drive SE, GW, KM, ML, MR, NE, SN, TD, TG). Bothell, Washington 98021 (US). LAW, Che-Leung; Declarations under Rule 4.17: 21823 30th Drive SE, Bothell, Washington 98021 (US). be — as to applicant's entitlement to apply for and granted a SENTER, Peter; 21823 30th Drive SE, Bothell, Washing- patent (Rule 4.170) ton 98021 (US). OKELEY, Nicole; 21823 30th Drive SE, Bothell, Washington 98021 (US). FIELD, Jessica; 21823 — as to the applicant's entitlement to claim the priority of the 30th Drive SE, Bothell, Washington 98021 (US). earlier application (Rule 4.17(iii)) (74) Agents: LIN, Min al.; Seattle Genetics, Inc., 21823 30th Published: et Drive SE, Bothell, Washington 98021 (US). — with international search report (Art 21(3)) Title: CANCER TREATMENT USING 2-DEOXY-2-FLUORO-L-FUCOSE IN COMBINATION WITH A CHECKPOINT (54) INHIBITOR Figure 11 100 AP- Untreated -M-2FF To 80- -A- Anti-PD1 91 60- m -0- 2FF + Anti-PD1 Cl) . 6' 1-1 a) 40 - .4t 2 a) il• 0 - 20- 11\" - - el 0. . . . C) 0 01 0 IN 1-1 O (57) : The present invention is an effective amount of 2-deoxy-2-fluoro-L-fucose 0 with a checkpoint inhibitor. 20 40 60 80 100 Days post tumor implant directed to methods for treating cancer comprising administering to a subject in need thereof or a prodrug thereof, or a pharmaceutically acceptable salt thereof, in combination
SG11201804263PA 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor SG11201804263PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562263228P 2015-12-04 2015-12-04
US201662308583P 2016-03-15 2016-03-15
US201662321857P 2016-04-13 2016-04-13
PCT/US2016/064783 WO2017096274A1 (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Publications (1)

Publication Number Publication Date
SG11201804263PA true SG11201804263PA (en) 2018-06-28

Family

ID=58797961

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201804263PA SG11201804263PA (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG10202005298RA SG10202005298RA (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202005298RA SG10202005298RA (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Country Status (13)

Country Link
US (1) US20180353524A1 (en)
EP (1) EP3383404A4 (en)
JP (1) JP6906520B2 (en)
KR (1) KR20180086233A (en)
CN (1) CN108289903B (en)
AU (1) AU2016362993A1 (en)
BR (1) BR112018011261A2 (en)
CA (1) CA3005997A1 (en)
EA (1) EA201891340A1 (en)
IL (1) IL259479B (en)
MX (1) MX2018006674A (en)
SG (2) SG11201804263PA (en)
WO (1) WO2017096274A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103402525B (en) 2010-08-05 2017-03-01 西雅图基因公司 The method suppressing protein fucosylation in vivo using fucose analogue
IL265800B2 (en) 2016-10-11 2023-10-01 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
MA50865A (en) * 2017-06-07 2020-04-15 Seattle Genetics Inc REDUCED SURFACE FUCOSYLATION T LYMPHOCYTES AND METHODS FOR THE PRODUCTION AND USE OF THE SAME
US11911404B2 (en) * 2017-10-13 2024-02-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune surveillance in melanoma
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
EP3897664A4 (en) * 2018-12-19 2022-12-07 Seagen Inc. Controlled fucosylation of antibodies
US20220305038A1 (en) * 2019-08-16 2022-09-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN111973749B (en) * 2020-09-07 2023-03-21 威海人生药业集团股份有限公司 Pharmaceutical composition for anti-tumor immunotherapy
WO2022221766A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN113274502B (en) * 2021-05-05 2023-01-03 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) Compositions for specific type three-negative breast cancer immunotherapy
WO2022236017A1 (en) * 2021-05-06 2022-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. L-fucose and anti-androgen receptor therapy for treatment of cancer
CN113413465B (en) * 2021-06-15 2022-06-03 北京大学 Application of fucosylation inhibitor in resisting inflammation caused by cancer
CN115466297B (en) * 2022-08-25 2023-07-07 青岛农业大学 Application of L-fucose and animal feed

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103402525B (en) * 2010-08-05 2017-03-01 西雅图基因公司 The method suppressing protein fucosylation in vivo using fucose analogue
WO2015069770A1 (en) 2013-11-05 2015-05-14 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer

Also Published As

Publication number Publication date
JP2019501145A (en) 2019-01-17
CA3005997A1 (en) 2017-06-08
CN108289903A (en) 2018-07-17
JP6906520B2 (en) 2021-07-21
EA201891340A1 (en) 2018-11-30
MX2018006674A (en) 2018-11-09
EP3383404A4 (en) 2019-07-31
BR112018011261A2 (en) 2018-11-21
CN108289903B (en) 2021-08-03
IL259479B (en) 2022-03-01
US20180353524A1 (en) 2018-12-13
WO2017096274A1 (en) 2017-06-08
EP3383404A1 (en) 2018-10-10
IL259479A (en) 2018-07-31
KR20180086233A (en) 2018-07-30
SG10202005298RA (en) 2020-07-29
AU2016362993A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201808125RA (en) Methods for solid tumor treatment
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201805755SA (en) Methods of administering hepcidin
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201901389XA (en) Combination therapy with glutaminase inhibitors
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201804268RA (en) Conjugates of quaternized tubulysin compounds
SG11201804587QA (en) Isoindole compounds
SG11201807977XA (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
SG11201810940XA (en) Methods of treating pancreatic cancer
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201803643TA (en) Virulence attenuated bacteria for treatment of malignant solid tumors
SG11201803816RA (en) Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders